Drug Trial Radar · NCT04709094
A Drug Interaction Study of Danicopan
Last checked: Nov 20, 2026Latest source record: Jan 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jul 28, 2019
Primary completion
Oct 14, 2019
Study completion Apr 17, 2020
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Achillion, a wholly owned subsidiary of Alexion; Celerion
- First posted
- Jan 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a 3-part study (Part 1, Part 2, Part 3) with each part being an open-label, fixed sequence, 2-period study in healthy adult participants.
Conditions
- Healthy
Interventions
DanicopanDrug
Danicopan was dosed as 2 x 100 milligram (mg) tablets.
WarfarinDrug
Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
BupropionDrug
Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
Ethinyl Estradiol/NorethindroneDrug
EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Warfarin Under Multiple Doses Of DanicopanTime frame: Up to 168 hours postdose
- Part 1: Maximum Observed Concentration (Cmax) Of Single-dose Warfarin Under Multiple Doses Of DanicopanTime frame: Up to 168 hours postdose
- Part 1: Time To Maximum Observed Concentration (Tmax) Of Single-dose Warfarin Under Multiple Doses Of DanicopanTime frame: Up to 168 hours postdose
- Part 2: AUC0-inf Of Single-dose Bupropion Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
- Part 2: Cmax Of Single-dose Bupropion Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
- Part 2: Tmax Of Single-dose Bupropion Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
- Part 3: AUC0-inf Of Single-dose EE/NET Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
- Part 3: Cmax Of Single-dose EE/NET Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
- Part 3: Tmax Of Single-dose EE/NET Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Study Site
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.